Home / Articles / The experience and prospects of melphalan and sarcolysin nano-sised drug delivery systems creation

The experience and prospects of melphalan and sarcolysin nano-sised drug delivery systems creation

Victor Pavlovich Krasnov 1
Victor Pavlovich Krasnov
, 
Marina Anatol'evna Korolyova 1
Marina Anatol'evna Korolyova
, 
Elena L'vovna Vodovozova 2
Elena L'vovna Vodovozova
1 I. Ya. Postovsky Institute of Organic Synthesis, Ural Branch of Russian Academy of Sciences, Ekaterinburg
2 Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow
10.1070/RC2013v082n08ABEH004358
Published 30 November 2012
Communication , Volume 82, Issue 8, 783-814
12
Share
Cite this
GOST
 | 
Cite this
GOST
Copy cite
Krasnov V. P., Korolyova M. A., Vodovozova E. L. The experience and prospects of melphalan and sarcolysin nano-sised drug delivery systems creation // Russian Chemical Reviews. 2013. Vol. 82. No. 8. pp. 783-814.
GOST all authors (up to 50)
Copy cite
Krasnov V. P., Korolyova M. A., Vodovozova E. L. The experience and prospects of melphalan and sarcolysin nano-sised drug delivery systems creation // Russian Chemical Reviews. 2013. Vol. 82. No. 8. pp. 783-814.
RIS
 | 
Cite this
RIS
Copy cite
TY - JOUR
DO - 10.1070/RC2013v082n08ABEH004358
UR - https://rcr.colab.ws/publications/10.1070/RC2013v082n08ABEH004358
TI - The experience and prospects of melphalan and sarcolysin nano-sised drug delivery systems creation
T2 - Russian Chemical Reviews
AU - Krasnov, Victor Pavlovich
AU - Korolyova, Marina Anatol'evna
AU - Vodovozova, Elena L'vovna
PY - 2013
DA - 2012/11/30
PB - ANO Editorial Board of the journal Uspekhi Khimii
SP - 783-814
IS - 8
VL - 82
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors)
Copy cite
@article{2013_Krasnov,
author = {Victor Pavlovich Krasnov and Marina Anatol'evna Korolyova and Elena L'vovna Vodovozova},
title = {The experience and prospects of melphalan and sarcolysin nano-sised drug delivery systems creation},
journal = {Russian Chemical Reviews},
year = {2013},
volume = {82},
publisher = {ANO Editorial Board of the journal Uspekhi Khimii},
month = {Nov},
url = {https://rcr.colab.ws/publications/10.1070/RC2013v082n08ABEH004358},
number = {8},
pages = {783--814},
doi = {10.1070/RC2013v082n08ABEH004358}
}
MLA
Cite this
MLA
Copy cite
Krasnov, Victor Pavlovich, et al. “The experience and prospects of melphalan and sarcolysin nano-sised drug delivery systems creation.” Russian Chemical Reviews, vol. 82, no. 8, Nov. 2013, pp. 783-814. https://rcr.colab.ws/publications/10.1070/RC2013v082n08ABEH004358.
Views / Visits / Downloads
37 / 37 / 9

Abstract

The results of experimental studies concerned with the development of nano-sized drug delivery systems of antitumor drugs sarcolysin and melphalan are generalized. The structures and biological activities of nanocarriers in comparison with unmodified drugs are discussed. Particular attention is given to the liposomes containing lipid derivatives of sarcolysin and melphalan in the lipid bilayer.

Bibliography --- 196 references.

References

1.
Nanocarriers as an emerging platform for cancer therapy
Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R.
Nature Nanotechnology , 2007
2.
2
A. A. Krasnovskii
Zhur. Fiz. Khim. , 1956
4.
Drug delivery and nanoparticles: Applications and hazards
de Jong
International Journal of Nanomedicine , 2008
5.
Factors Controlling Nanoparticle Pharmacokinetics: An Integrated Analysis and Perspective
Moghimi S.M., Hunter A.C., Andresen T.L.
Annual Review of Pharmacology and Toxicology , 2012
6.
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho K., Wang X., Nie S., Chen Z.(., Shin D.M.
Clinical Cancer Research , 2008
7.
7
E. Rabinowitch
"Photosynthesis" , 1956
8.
Nanoparticles in cellular drug delivery
Faraji A.H., Wipf P.
Bioorganic and Medicinal Chemistry , 2009
9.
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi S.M., Hunter A.C., Murray J.C.
Pharmacological Reviews , 2001
13.
Material properties in complement activation
Moghimi S.M., Andersen A.J., Ahmadvand D., Wibroe P.P., Andresen T.L., Hunter A.C.
Advanced Drug Delivery Reviews , 2011
14.
Aminoacids and Peptides Containing the Di-(2-chloroethyl)amino-group
Rasteikiene L., Dagiene M., Knunyants I.L.
Russian Chemical Reviews , 1970
16.
16
A. A. Krasnovskii
Dokl. Akad. Nauk SSSR , 1949
17.
17
V. B. Evstigneev
Dokl. Akad. Nauk SSSR , 1958
18.
18
A. A. Krasnovskii
Dokl. Akad. Nauk SSSR , 1951
19.
19
A. A. Krasnovskii
Dokl. Akad. Nauk SSSR , 1959
20.
20
A. A. Krasnovskii
Dokl. Akad. Nauk SSSR , 1954
21.
21
A. A. Krasnovskii
Dokl. Akad. Nauk SSSR , 1958
22.
22
A. A. Krasnovskii
Dokl. Akad. Nauk SSSR , 1958
23.
Cyto-active amino-acid and peptide derivatives. Part I. Substituted phenylalanines
Bergel F., Stock J.A.
Journal of the Chemical Society (Resumed) , 1954
24.
24
M. S. Ashkinazi
Dokl. Akad. Nauk SSSR , 1951
25.
25
G. W. Robinson
J. Chem. Phys. , 1955
26.
26
B. Ya. Dain
1957
27.
27
A. A. Krasnovskii
Biofizika , 1956
28.
STUDIES ON THE ANTI-TUMOUR ACTIVITY OF p-DI-(2-CHLOROETHYL) AMINOPHENYLALANINE (SARCOLYSINE)
Larionov L.F., Khokhlov A.S., Shkodinskaja E.N., Vasina O.S., Troosheikina V.I., Novikova M.A.
The Lancet , 1955
30.
30
V. B. Evstigneev
Dokl. Akad. Nauk SSSR , 1954
31.
The antitumor activity of the optic isomers of sarcolysin
Trusheikina V.I.
Bulletin of Experimental Biology and Medicine , 1958
32.
32
A. A. Krasnovskii
Dokl. Akad. Nauk SSSR , 1952
33.
33
M. B. Neiman
"Issledovanie Mekhanizma Okisleniya Butana" (Research on the Mechanism of the Oxidation of Butane) , 1939
35.
On the antitumor activity of certain derivatives of sarcolysin (DL-n-di-(2-chlorethyl) aminophenylalanine)
Vodolazskaya N.A., Novikova M.A., Shkodinskaya E.N., Vasina O.S., Berlin A.Y., Larionov L.F.
Bulletin of Experimental Biology and Medicine , 1957
37.
37
L. M. Kosobutskaya
Dokl. Akad. Nauk SSSR , 1950
38.
38
V. B. Evstigneev
Dokl. Akad. Nauk SSSR , 1956
39.
39
V. F. Gachkovskii
Biofizika , 1959
40.
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., Kropff M., Spicka I., Petrucci M.T., Palumbo A., Samoilova O.S., Dmoszynska A., Abdulkadyrov K.M., Schots R., Jiang B., Mateos M., et. al.
New England Journal of Medicine , 2008
41.
Chemotherapy of multiple myeloma: Melphalan—40 years old and still going strong
Bergsagel P.L.
Biology of Blood and Marrow Transplantation , 2003
42.
42
L. K. Obukhova
Izv. Akad. Nauk SSSR, Otd. Khim. Nauk , 1960
44.
Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases
van Etten B., de Wilt J.H., Brunstein F., Eggermont A.M., Verhoef C.
European Journal of Surgical Oncology , 2009
45.
Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Berenson J.R., Yang H.H., Sadler K., Jarutirasarn S.G., Vescio R.A., Mapes R., Purner M., Lee S., Wilson J., Morrison B., Adams J., Schenkein D., Swift R.
Journal of Clinical Oncology , 2006
46.
Clinical applications of TNF-α in cancer
Lejeune F.J., Rüegg C., Liénard D.
Current Opinion in Immunology , 1998
49.
49
A. A. Krasnovskii
Biofizika , 1958
50.
50
G. Glacomello
Gazzetta. , 1935
51.
Goldenberg G.J., Moore M.J.
1997
52.
Aneugenic potential of the nitrogen mustard analogues melphalan, chlorambucil and p-N,N-bis(2-chloroethyl)aminophenylacetic acid in cell cultures in vitro
Efthimiou M., Andrianopoulos C., Stephanou G., Demopoulos N.A., Nikolaropoulos S.S.
Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis , 2007
53.
Cardiotoxicity of Antitumor Drugs†
Menna P., Salvatorelli E., Minotti G.
Chemical Research in Toxicology , 2008
54.
Melphalan
Feyns L.V.
Profiles of Drug Substances, Excipients and Related Methodology , 1984
55.
55
G. A. Bogdanovskii
1958
56.
The hydrolysis of l-phenylalanine mustard (melphalan)
Stout S.A., Riley C.M.
International Journal of Pharmaceutics , 1985
57.
Kinetic analysis of the reaction of melphalan with water, phosphate, and glutathione.
Bolton M.G., Hilton J., Robertson K.D., Streeper R.T., Colvin O.M., Noe D.A.
Drug Metabolism and Disposition , 1993
59.
59
H. Linshitz
"Research in Photosynthesis" , 1957
61.
A Monofunctional Derivative of Melphalan:  Preparation, DNA Alkylation Products, and Determination of the Specificity of Monoclonal Antibodies That Recognize Melphalan−DNA Adducts
Tilby M.J., McCartney H., Gould K.A., O'Hare C.C., Hartley J.A., Hall A.G., Golding B.T., Lawley P.D.
Chemical Research in Toxicology , 1998
63.
Qualitative study ofin vivo melphalan adduct formation in the rat by miniaturized column-switching liquid chromatography coupled with electrospray mass spectrometry
Van den Driessche B., Lemière F., Van Dongen W., Van der Linden A., Esmans E.L.
Journal of Mass Spectrometry , 2004
64.
Dimopoulos M.A., Souliotis V.L., Anagnostopoulos A., Bamia C., Pouli A., Baltadakis I., Terpos E., Kyrtopoulos S.A., Sfikakis P.P.
Haematologica , 2007
65.
Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance
McHugh P.J., Spanswick V.J., Hartley J.A.
The Lancet Oncology , 2001
66.
66
V. B. Evstigneev
Dokl. Akad. Nauk SSSR , 1950
67.
Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma
Spanswick V.J., Craddock C., Sekhar M., Mahendra P., Shankaranarayana P., Hughes R.G., Hochhauser D., Hartley J.A.
Blood , 2002
69.
The role of glutathione in cancer
Balendiran G.K., Dabur R., Fraser D.
Cell Biochemistry and Function , 2004
71.
Metabolism of melphalan by rat liver microsomal glutathione S-transferase
Zhang J., Ye Z., Lou Y.
Chemico-Biological Interactions , 2005
72.
72
A. F. Lukovnikov
"Starenie i Stabilizatsiya Polimerov" (Aging arid Stabilisation of Polymers) , 1963
73.
Clinical studies of reversal of drug resistance based on glutathione
Calvert P., Yao K., Hamilton T.C., O’Dwyer P.J.
Chemico-Biological Interactions , 1998
75.
75
V. B. Evstigneev
Dokl. Akad. Nauk SSSR , 1950
76.
The dawning era of polymer therapeutics
Duncan R.
Nature Reviews Drug Discovery , 2003
77.
Nanoscale polymer carriers to deliver chemotherapeutic agents to tumours
Cegnar M., Kristl J., Kos J.
Expert Opinion on Biological Therapy , 2005
78.
Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery
Sinha R., Kim G.J., Nie S., Shin D.M.
Molecular Cancer Therapeutics , 2006
79.
Polymer conjugates as anticancer nanomedicines
Duncan R.
Nature Reviews Cancer , 2006
80.
Methoxy Polyethylene Glycol-Epoetin Beta
Curran M.P., McCormack P.L.
Drugs , 2008
81.
Certolizumab pegol for the treatment of Crohn's disease.
Sandborn W.J., Feagan B.G., Stoinov S., Honiball P.J., Rutgeerts P., Mason D., Bloomfield R., Schreiber S.
New England Journal of Medicine , 2007
82.
Biodegradable polymeric nanoparticles as drug delivery devices.
Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., Rudzinski W.E.
Journal of Controlled Release , 2001
83.
83
A. A. Krasnovskii
Dokl. Akad. Nauk SSSR , 1947
84.
Development of injectable antitumor microspheres based on polyphosphazene
Goedemoed J.H., Mense E.H., de Groot K., Claessen A.M., Scheper R.J.
Journal of Controlled Release , 1991
85.
Development of implantable antitumor devices based on polyphosphazenes
Goedemoed J.H., De Groot K.
Makromolekulare Chemie Macromolecular Symposia , 1988
86.
Development of implantable antitumor devices based on polyphosphazenes, II
Goedemoed J.H., de Groot K., Claessen A.M., J. Scheper R.
Journal of Controlled Release , 1991
87.
Polymer therapeutics: Clinical applications and challenges for development
Vicent M.J., Ringsdorf H., Duncan R.
Advanced Drug Delivery Reviews , 2009
89.
Polymer–drug conjugates: Progress in polymeric prodrugs
Khandare J., Minko T.
Progress in Polymer Science , 2006
91.
Polymeric Nanocarriers: New Endeavors for the Optimization of the Technological Aspects of Drugs
Sosnik A., Carcaboso A., Chiappetta D.
Recent Patents on Biomedical Engineering , 2008
92.
Polymer–drug conjugates: towards a novel approach for the treatment of endrocine-related cancer
Duncan R., Vicent M.J., Greco F., Nicholson R.I.
Endocrine-Related Cancer , 2005
93.
Rational Design of Multifunctional Polymer Therapeutics for Cancer Theranostics
Ofek P., Miller K., Eldar-Boock A., Polyak D., Segal E., Satchi-Fainaro R.
Israel Journal of Chemistry , 2010
94.
Targeting of Drugs to Cell Surface Receptors
Říhová B.
Critical Reviews in Biotechnology , 1997
96.
Release from polymeric prodrugs: Linkages and their degradation
D'Souza A.J., Topp E.M.
Journal of Pharmaceutical Sciences , 2004
97.
Polymeric anticancer drugs with pH-controlled activation
Ulbrich K.
Advanced Drug Delivery Reviews , 2004
98.
Tumor Vascular Permeability, Accumulation, and Penetration of Macromolecular Drug Carriers
Dreher M.R., Liu W., Michelich C.R., Dewhirst M.W., Yuan F., Chilkoti A.
Journal of the National Cancer Institute , 2006
99.
Effective drug delivery by PEGylated drug conjugates
Greenwald R.B., Choe Y.H., McGuire J., Conover C.D.
Advanced Drug Delivery Reviews , 2003
100.
100
V. V. Zolotarev
Chem. Abs. , 1941
102.
N-(2-Hydroxypropyl) methacrylamide Copolymer Conjugates
Duncan R.
Drugs and the Pharmaceutical Sciences , 2005
103.
Intracellular targeting of polymer-bound drugs for cancer chemotherapy
NORI A., KOPECEK J.
Advanced Drug Delivery Reviews , 2005
104.
Preparation and investigation of cross-linked copolymers containing antitumour agents
Zacharieva E.I., Georgieva M.P., Kabaivanov V.S., Popov D.V.
Biomaterials , 1983
105.
105
F. F. Litvin
Dokl. Akad. Nauk SSSR , 1958
106.
Polymer‐bound derivatives of sarcolysin and their antitumour activity against mouse and human leukaemia in vitro
Ulbrich K., Zacharieva E.I., Kopeček J., Hume I.C., Duncan R.
Die Makromolekulare Chemie , 1987
108.
Macromolecular prodrugs for use in targeted cancer chemotherapy: melphalan covalently coupled to N- (2-hydroxypropyl) methacrylamide copolymers
Duncan R., Hume I.C., Yardley H.J., Flanagan P.A., Ulbrich K., Subr V., Strohalm J.
Journal of Controlled Release , 1991
110.
110
M. F. Shostakovskii
Dokl. Akad. Nauk SSSR , 1960
111.
Self-immolative dendrimers as novel drug delivery platforms
Shabat D.
Journal of Polymer Science, Part A: Polymer Chemistry , 2006
113.
Structure Activity Relationship of Dendrimer Microbicides with Dual Action Antiviral Activity
Tyssen D., Henderson S.A., Johnson A., Sterjovski J., Moore K., La J., Zanin M., Sonza S., Karellas P., Giannis M.P., Krippner G., Wesselingh S., McCarthy T., Gorry P.R., Ramsland P.A., et. al.
PLoS ONE , 2010
114.
SPL7013 Gel (VivaGel®) Retains Potent HIV-1 and HSV-2 Inhibitory Activity following Vaginal Administration in Humans
Price C.F., Tyssen D., Sonza S., Davie A., Evans S., Lewis G.R., Xia S., Spelman T., Hodsman P., Moench T.R., Humberstone A., Paull J.R., Tachedjian G.
PLoS ONE , 2011
115.
Self-immolative linkers in polymeric delivery systems
Blencowe C.A., Russell A.T., Greco F., Hayes W., Thornthwaite D.W.
Polymer Chemistry , 2011
116.
116
V. B. Evstigneev
Dokl. Akad. Nauk SSSR , 1957
117.
Single-Triggered Trimeric Prodrugs
Haba K., Popkov M., Shamis M., Lerner R.A., Barbas C.F., Shabat D.
Angewandte Chemie - International Edition , 2005
118.
Remarkable drug-release enhancement with an elimination-based AB3 self-immolative dendritic amplifier
Sagi A., Segal E., Satchi-Fainaro R., Shabat D.
Bioorganic and Medicinal Chemistry , 2007
119.
Bioactivation of carbamate-based 20(S)-camptothecin prodrugs
Pessah N., Reznik M., Shamis M., Yantiri F., Xin H., Bowdish K., Shomron N., Ast G., Shabat D.
Bioorganic and Medicinal Chemistry , 2004
121.
Cyclodextrins as Drug Carrier Molecule: A Review
Arun Rasheed
Scientia Pharmaceutica , 2008
122.
122
S. R. Rafikov
Izv. Akad. Nauk SSSR, Otd. Khim. Nauk , 1953
123.
123
V. V. Levchenko
Zhur. Obshch. Khim. , 1952
124.
124
V. V. Levchenko
Zhur. Obshch. Khim. , 1952
125.
The effects of 2-hydroxypropyl-β-cyclodextrin on the solubility and stability of chlorambucil and melphalan in aqueous solution
Loftsson T., Björnsdóttir S., Pálsdóttir G., Bodor N.
International Journal of Pharmaceutics , 1989
126.
10.1002/(SICI)1520-6017(200002)89:2<275::AID-JPS15>3.0.CO;2-C
129.
Preclinical comparison of intravenous melphalan pharmacokinetics administered in formulations containing either (SBE)7 m-β-cyclodextrin or a co-solvent system
Koltun M., Morizzi J., Katneni K., Charman S.A., Shackleford D.M., McIntosh M.P.
Biopharmaceutics and Drug Disposition , 2010
130.
130
J. Wiemann
Bull. Soc. chim. France , 1958
131.
Pharmaceutical Applications of Cyclodextrins. 2. In Vivo Drug Delivery
Rajewski R.A., Stella V.J.
Journal of Pharmaceutical Sciences , 2002
132.
Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization.
Loftsson T., Brewster M.E.
Journal of Pharmaceutical Sciences , 1996
135.
Lipid-based vehicles for the oral delivery of poorly water soluble drugs
Humberstone A.J., Charman W.N.
Advanced Drug Delivery Reviews , 1997
139.
Recent advances with liposomes as pharmaceutical carriers
Torchilin V.P.
Nature Reviews Drug Discovery , 2005
140.
Development of Multifunctional Nanoparticles for Targeted Drug Delivery and Noninvasive Imaging of Therapeutic Effect
Sajja H., East M., Mao H., Wang Y., Nie S., Yang L.
Current Drug Discovery Technologies , 2009
141.
Developments in liposomal drug delivery systems
Maurer N., Fenske D.B., Cullis P.R.
Expert Opinion on Biological Therapy , 2001
142.
142
1913
143.
143
Friedl.
146.
146
V. V. Korshak
Dokl. Akad. Nauk SSSR , 1952
148.
Liposomes revisited
Lasic D.D., Papahadjopoulos D.
Science , 1995
149.
149
V. V. Korshak
Dokl. Akad. Nauk SSSR , 1954
150.
150
Ya. E. Bernadskaya
"Iskusstvennoe Volokno" (Artificial Fibres) , 1952
152.
152
W. Albert
Trans. Electrochem. Soc. , 1943
153.
153
1899
154.
154
Friedl.
157.
157
1903
159.
159
J. Tafel
Z. Elektrochem. , 1911
161.
161
Friedl.
162.
Reduced Toxicity and Superior Therapeutic Activity of a Mitomycin C Lipid-Based Prodrug Incorporated in Pegylated Liposomes
Gabizon A.A., Tzemach D., Horowitz A.T., Shmeeda H., Yeh J., Zalipsky S.
Clinical Cancer Research , 2006
163.
163
Friedl.
164.
164
1917
165.
Liposomes loaded with lipophilic prodrugs of methotrexate and melphalan as convenient drug delivery vehicles
Kuznetsova N., Kandyba A., Vostrov I., Kadykov V., Gaenko G., Molotkovsky J., Vodovozova E.
Journal of Drug Delivery Science and Technology , 2009
166.
166
1917
168.
Increase in sarcolysin antitumor activity by transforming it into a lipid derivative and incorporation in the membrane of liposomes containing a carbohydrate vector
Kozlov A.M., Korchagina E.Y., Vodovozova E.L., Bovin N.V., Molotkovskii Y.G., Syrkin A.B.
Bulletin of Experimental Biology and Medicine , 1997
169.
169
Friedl.
170.
Antitumour activity of cytotoxic liposomes equipped with selectin ligand SiaLeX, in a mouse mammary adenocarcinoma model
Vodovozova E.L., Moiseeva E.V., Grechko G.K., Gayenko G.P., Nifant'ev N.E., Bovin N.V., Molotkovsky J.G.
European Journal of Cancer , 2000
171.
Selectins—an emerging target for drug delivery
Ehrhardt C., Kneuer C., Bakowsky U.
Advanced Drug Delivery Reviews , 2004
172.
Methylation of the phosphate oxygen moiety of phospholipid‐methoxy(polyethylene glycol) conjugate prevents PEGylated liposome‐mediated complement activation and anaphylatoxin production
Moein Moghimi S., Hamad I., Andresen T.L., Jørgensen K., Szebeni J., Moein Moghimi S., Hamad I., Andresen T.L., Jørgensen K., Szebeni J.
FASEB Journal , 2006
173.
Hemocompatibility of liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the lipid bilayer
Kuznetsova N.R., Sevrin C., Lespineux D., Bovin N.V., Vodovozova E.L., Mészáros T., Szebeni J., Grandfils C.
Journal of Controlled Release , 2012
174.
Qualitative Analysis of Total Complement Activation by Nanoparticles
Neun B.W., Dobrovolskaia M.A.
Methods in Molecular Biology , 2010
176.
176
G. V. Samsonov
"Metody Ispytaniya na Mikrotverdost' i Pribory" (Methods of Microhardness Testing and Apparatus) , 1965
177.
177
J. Henry
Proc. R. Irish Acad. , 1945
178.
Prodrug Strategies in Anticancer Chemotherapy
Kratz F., Müller I., Ryppa C., Warnecke A.
ChemMedChem , 2008
179.
179
Chem. Abs. , 1947
180.
180
1946
181.
Synergistic effect of K-18 and concomitant hyperthermia for treatment of lewis lung carcinoma in mice
Tamada R., Kai H., Sugimachi K., Takenaka K., Hiramoto Y., Inokuchi K.
Surgery Today , 1985
182.
182
1947
183.
183
Chem. Abs. , 1947
184.
The in vitro and in vivo anti-tumour activity of N-AcMEL-(Fab')2 conjugates
Smyth M., Pietersz G., McKenzie I.
British Journal of Cancer , 1987
188.
188
Chem. Abs. , 1955
190.
Antibody–cytotoxic agent conjugates for cancer therapy
Chen J., Jaracz S., Zhao X., Chen S., Ojima I.
Expert Opinion on Drug Delivery , 2005
192.
Design and Synthesis of a Nitrogen Mustard Derivative Stabilized by Apo-neocarzinostatin
Urbaniak M.D., Bingham J.P., Hartley J.A., Woolfson D.N., Caddick S.
Journal of Medicinal Chemistry , 2004
193.
Synthetic Ligands for Apo-Neocarzinostatin
Caddick S., Muskett F.W., Stoneman R.G., Woolfson D.N.
Journal of the American Chemical Society , 2006
194.
Protein–Small Molecule Interactions in Neocarzinostatin, the Prototypical Enediyne Chromoprotein Antibiotic
Baker J.R., Woolfson D.N., Muskett F.W., Stoneman R.G., Urbaniak M.D., Caddick S.
ChemBioChem , 2007